The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | DEDALUS: induction chemo-IO, reduced dose RT + consolidation IO for NSCLC
Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the updated efficacy results and post-hoc analysis of lymphopenia incidence from the DEDALUS trial (NCT05128630), a Phase II non-comparative trial evaluating induction chemoimmunotherapy (chemo-IO) followed by reduced dose radiation and immunotherapy (IO) in unfit, frail, or elderly patients with unresectable stage 3 non-small cell lung cancer (NSCLC). Dr Filippi highlights that while the treatment regimen is not without toxicity, patients who can tolerate it and receive radiation therapy have a high chance of being progression-free with good overall survival, and that selecting patients and preventing lymphopenia and hematological toxicity is crucial to improve outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
